vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and IT TECH PACKAGING, INC. (ITP). Click either name above to swap in a different company.
IT TECH PACKAGING, INC. is the larger business by last-quarter revenue ($25.6M vs $16.1M, roughly 1.6× Journey Medical Corp). IT TECH PACKAGING, INC. runs the higher net margin — -5.7% vs -7.8%, a 2.1% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 2.1%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 10.5%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
IT TECH PACKAGING, INC. is a paper manufacturing enterprise primarily operating in China. It produces and distributes a diverse portfolio of paper products including corrugated packaging paper, boxboard, and printing-use cultural paper, serving sectors such as consumer goods packaging, logistics, and commercial printing across its core market.
DERM vs ITP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $25.6M |
| Net Profit | $-1.2M | $-1.4M |
| Gross Margin | — | 7.9% |
| Operating Margin | -2.8% | -3.9% |
| Net Margin | -7.8% | -5.7% |
| Revenue YoY | 27.3% | 2.1% |
| Net Profit YoY | -182.0% | 26.6% |
| EPS (diluted) | $-0.04 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | — | ||
| Q3 25 | $17.0M | $25.6M | ||
| Q2 25 | $15.0M | $24.8M | ||
| Q1 25 | $13.1M | $10.9M | ||
| Q4 24 | $12.6M | $17.6M | ||
| Q3 24 | $14.6M | $25.1M | ||
| Q2 24 | $14.9M | $26.2M | ||
| Q1 24 | $13.0M | $6.9M |
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-2.3M | $-1.4M | ||
| Q2 25 | $-3.8M | $-2.0M | ||
| Q1 25 | $-4.1M | $-3.5M | ||
| Q4 24 | $1.5M | $-4.0M | ||
| Q3 24 | $-2.4M | $-2.0M | ||
| Q2 24 | $-3.4M | $-77.7K | ||
| Q1 24 | $-10.4M | $-3.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | 82.3% | 6.3% | ||
| Q3 24 | 63.9% | 7.6% | ||
| Q2 24 | 56.0% | 12.4% | ||
| Q1 24 | 47.7% | 5.8% |
| Q4 25 | -2.8% | — | ||
| Q3 25 | -9.0% | -3.9% | ||
| Q2 25 | -19.2% | -7.1% | ||
| Q1 25 | -25.3% | -31.0% | ||
| Q4 24 | 17.7% | -21.5% | ||
| Q3 24 | -19.8% | -5.8% | ||
| Q2 24 | -19.7% | 2.1% | ||
| Q1 24 | -77.4% | -51.0% |
| Q4 25 | -7.8% | — | ||
| Q3 25 | -13.6% | -5.7% | ||
| Q2 25 | -25.3% | -7.9% | ||
| Q1 25 | -31.0% | -32.2% | ||
| Q4 24 | 12.1% | -22.9% | ||
| Q3 24 | -16.3% | -7.9% | ||
| Q2 24 | -22.6% | -0.3% | ||
| Q1 24 | -80.1% | -54.6% |
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.09 | $-0.11 | ||
| Q2 25 | $-0.16 | $-0.16 | ||
| Q1 25 | $-0.18 | $-0.35 | ||
| Q4 24 | $0.10 | $-0.40 | ||
| Q3 24 | $-0.12 | $-0.20 | ||
| Q2 24 | $-0.17 | $-0.01 | ||
| Q1 24 | $-0.53 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | — |
| Total DebtLower is stronger | $25.3M | $4.7M |
| Stockholders' EquityBook value | $31.9M | $152.0M |
| Total Assets | $94.6M | $175.7M |
| Debt / EquityLower = less leverage | 0.79× | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | — | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $23.9M | — | ||
| Q1 24 | $24.1M | — |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | $4.7M | ||
| Q2 25 | $25.1M | $4.7M | ||
| Q1 25 | $25.0M | $4.7M | ||
| Q4 24 | $24.9M | $4.7M | ||
| Q3 24 | $19.8M | $8.9M | ||
| Q2 24 | $19.7M | $11.3M | ||
| Q1 24 | $14.7M | $11.4M |
| Q4 25 | $31.9M | — | ||
| Q3 25 | $25.9M | $152.0M | ||
| Q2 25 | $19.2M | $152.3M | ||
| Q1 25 | $21.5M | $152.8M | ||
| Q4 24 | $20.1M | $156.1M | ||
| Q3 24 | $10.9M | $164.3M | ||
| Q2 24 | $11.3M | $163.5M | ||
| Q1 24 | $13.0M | $164.3M |
| Q4 25 | $94.6M | — | ||
| Q3 25 | $85.2M | $175.7M | ||
| Q2 25 | $81.2M | $175.2M | ||
| Q1 25 | $85.0M | $175.2M | ||
| Q4 24 | $80.2M | $177.5M | ||
| Q3 24 | $64.0M | $190.0M | ||
| Q2 24 | $65.2M | $191.4M | ||
| Q1 24 | $66.6M | $177.5M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | 0.03× | ||
| Q2 25 | 1.30× | 0.03× | ||
| Q1 25 | 1.16× | 0.03× | ||
| Q4 24 | 1.24× | 0.03× | ||
| Q3 24 | 1.81× | 0.05× | ||
| Q2 24 | 1.75× | 0.07× | ||
| Q1 24 | 1.13× | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $1.5M |
| Free Cash FlowOCF − Capex | — | $1.5M |
| FCF MarginFCF / Revenue | — | 5.9% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | — | ||
| Q3 25 | $-2.4M | $1.5M | ||
| Q2 25 | $-942.0K | $1.4M | ||
| Q1 25 | $-2.8M | $-2.5M | ||
| Q4 24 | $2.2M | $3.5M | ||
| Q3 24 | $-1.2M | $1.5M | ||
| Q2 24 | $-5.2M | $721.9K | ||
| Q1 24 | $-5.0M | $624.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $-2.5M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | — | $1.2M | ||
| Q2 24 | — | $668.3K | ||
| Q1 24 | — | $615.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | 5.9% | ||
| Q2 25 | — | 5.4% | ||
| Q1 25 | — | -22.8% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 2.5% | ||
| Q1 24 | — | 9.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
ITP
Segment breakdown not available.
